Post Profile






Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
read more

share

Related Posts


Lenvatinib Shows Promise for Patients with Radioiodine-Refractory Thyroid Cancer

Health : Newswise Medical News

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced ...

Breast Cancer Relapse Prevented For Up To 8 Years By Aromatase Inhibitor Letrozole

Health : Medical News Today

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the ris...

Tyverb(R)/Tykerb(R) Plus Letrozole Significantly Delayed Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer

Health : Medical News Today

New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Combination of Everolimus and Exemestane Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD ...

Comments


Copyright © 2016 Regator, LLC